The VEGFR-1 and VEGFR-2 levels were assessed simultaneously in 57 patients, with repeated measurements taken in different stroke phases (blood samples were drawn once in 32 patients and 2–3 times in 25 patients at different disease phases) and in 20 control subjects, while VEGF-A values were evaluated in a separate group of 51 patients and in an independent control group of 20 patients (Table 2). The gene discussed is FLT1; the disease is stroke disorder.